Formulation development and optimization of sustained release matrix tablet of Itopride HCl by response surface methodology and its evaluation of release kinetics  by Bose, Anirbandeep et al.
Saudi Pharmaceutical Journal (2013) 21, 201–213King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEFormulation development and optimization
of sustained release matrix tablet of Itopride HCl
by response surface methodology and its evaluation
of release kineticsAnirbandeep Bose a,b,*, Tin Wui Wong a,b, Navjot Singh ca Particle Design Research Group, Universiti Teknologi MARA, 42300 Puncak Alam, Selangor, Malaysia
b Non-Destructive Biomedical and Pharmaceutical Research Centre, Universiti Teknologi MARA, 42300 Puncak Alam,
Selangor, Malaysia
c NRI Institute of Pharmacy, Bhopal 462021, IndiaReceived 19 February 2012; accepted 30 March 2012
Available online 12 April 2012*
sit
D
Te
E
Pe
13
htKEYWORDS
Itopride HCl;
Response surface
methodology;
HPMC;
Release kineticsCorresponding author at: P
i Teknologi MARA, 42300 P
estructiveBiomedical andPha
knologi MARA, 42300 Punc
-mail address: anirbandeep@
er review under responsibilit
Production an
19-0164 ª 2012 King Saud U
tp://dx.doi.org/10.1016/j.jspsarticle De
uncak Al
rmaceuti
ak Alam,
gmail.co
y of King
d hostin
niversity
.2012.03.0Abstract The objective of this present investigation was to develop and formulate sustained release
(SR) matrix tablets of Itopride HCl, by using different polymer combinations and ﬁllers, to optimize
by Central Composite Design response surface methodology for different drug release variables and
to evaluate drug release pattern of the optimized product. Sustained release matrix tablets of various
combinationswere preparedwith cellulose-based polymers: hydroxy propylmethyl cellulose (HPMC)
and polyvinyl pyrolidine (pvp) and lactose as ﬁllers. Study of pre-compression and post-compression
parameters facilitated the screening of a formulation with best characteristics that underwent here
optimization study by response surfacemethodology (Central CompositeDesign). The optimized tab-
let was further subjected to scanning electron microscopy to reveal its release pattern. The in vitro
study revealed that combining of HPMCK100M (24.65MG) with pvp(20 mg)and use of LACTOSE
as ﬁller sustained the action more than 12 h. The developed sustained release matrix tablet of
improved efﬁcacy can perform therapeutically better than a conventional tablet.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.sign Research Group, Univer-
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061. IntroductionMatrix tablet is one of the most convenient approaches for the
preparation of the sustained release dosage forms. In actual
practice direct compression of drug, retardant material, addi-
tives is done to form a tablet in which drug particles are
embedded in the matrix core of the retardant. Dry or wet gran-
ulation technique may also be employed for the preparation ofier B.V. All rights reserved.
202 A. Bose et al.this type of tablets. Among the different strategies to prolong
the drug action, formulation of matrix tablet has gained im-
mense popularity now a days because it has the advantage of
simple processing and a low cost of fabrication (Reddy
et al., 2003).The loading dose is most convenient to include
in a separate layer or in a coating applied to the tablet. An
equation was developed by Higuchi (1961, 1963) to explain
the drug release from the matrix base, which was later on
extrapolated to the diffusion of solid drug dispersed in homog-
enous polymer matrices. Sustained release matrix tablet can be
prepared in two ways, one is direct compression of the powder
blend containing the drug, polymer and other additives, and
another one involves granulation prior to compression. Selec-
tion of the proper method depends on the properties of the
drug, polymer and other ingredients.
There are three primary mechanisms by which active agents
can be released from a delivery system: diffusion, degradation,
and swelling followed by diffusion. Any or all of these mecha-
nisms may occur in a given release system. Diffusion occurs
when a drug or other active agent passes through the polymer
that forms the controlled-release device. The diffusion can occur
on a macroscopic scale as through pores in the polymer matrix
or on a molecular level, by passing between polymer chains.
Development of a sustained release tablet dosage form is
based on many statistical experiments which are recognized
as useful techniques to design an optimized formulation with
an appropriate dissolution rate in a short time period and a
minimum number of trials. For this reason, a computer based
optimization technique with a response surface methodology
(RSM) utilizing a polynomial equation and artiﬁcial neural
network (ANN) has been widely used (Ghosh et al., 2008;
Mandal et al., 2007; Nazzal et al., 2002; Hamed and Sakr,
2001; Fassihi and Ritschel, 1993; Takayama et al., 2003; Sastry
and Khan, 1998; Huang et al., 2004; Bozic et al., 1997). Differ-
ent types of screening designs have been used for preformula-
tion evaluation. On oral administration, Itopride is rapidly and
extensively absorbed and peak serum concentrations are
achieved within 35 min after oral dosing. Thus it has a rapid
onset of action, unlike cisapride and mosapride, which take
around 60 min to reach peak plasma concentrations . The half
life of Itopride is about 6 h (Banka, 2003). It is excreted mainly
by the kidneys as metabolites and unchanged drug. Due to its
short half life it is excellent for the formulation of matrix tablet
sustained release formulation.
2. Materials and methods
2.1. Materials
2.1.1. Materials used in the preparation 50 mg Itopride SRI) Itopride HCl: Provided by Theon
Pharmaceuticals Pvt. Ltd., HPIII) HPMC K100
M/K15M/K4M:
P
Krovided by Stadmed Pvt. Ltd.,
olkataIV) PVPK 30: -Do-VI) Talcum powder: -Do-IX) Magnesium stearate: -Do-X) Lactose: -Do-XII) Isopropyl alcohol: Merck, Germany.2.2. Development of sustained release formulation of Itopride
50 mg
The most effective method of modulating drug release is to
include it in a matrix system. The matrix tablet was prepared
via wet granulation method. Many polymers have been used
in the formulation of matrix based controlled released drug
delivery system. Reports are found on the use of hydrophilic
polymers like HPMC for the preparation of SR formulation
of different drugs. Different viscosity grades of polymers are
widely used for designing oral controlled drug delivery sys-
tem because their ﬂexibility to provide a desired drug release
proﬁle and cost effectiveness and broad regulatory accep-
tance. However, the use of hydrophilic matrix alone for
extending drug release for the highly water soluble drug is re-
stricted due to rapid diffusion of dissolved drug through the
hydrophilic gel network, for such drug inclusion of the bin-
der like PVP K30 becomes essential in the matrix systems.
Hence, in the present work, an attempt has been made to
formulate the extended release matrix tablets of Itopride
using different ratios of three different viscosity grades of
HPMC polymer with and without binder (PVP K30). Four-
teen formulations of Itopride was developed as shown in Ta-
ble 1 . The granules were formulated according to wet
granulation method .All the raw drugs and excipients were
passed through a 40 mesh size sieve separately. Active drugs,
the polymers and lactose were mixed thoroughly. The PVP
K30 paste was formed using granulating ﬂuid IPA .The
PVP paste was thoroughly mixed with the mixture of drugs
and polymers. The mixing product was passed through the
20 mesh size sieve. The granules were dried at 40 C in an
oven dryer for 30 min .The granules thus formed were also
passed through a 18 mesh size sieve. The granules were then
mixed with lubricating agent talcum and magnesium state be-
fore ﬁnal compression.
2.3. Micromeritic properties of granules for 50 mg Itopride HCl
SR formulation
2.3.1. Angle of repose
Angle f repose can be determined by the ﬁxed funnel and free
standing cone methods, the method employed a funnel that
was secured with its tip at a given height, H above the graph
paper that was placed on a ﬂat horizontal surface. Powder
or granules were carefully poured through the funnel until
the apex at the conical pile just touched the tip of the funnel
.Thus, with R being the radius of the base of the conical pile
tan1= H/R. Where, H and R are the height and radius of
the powder cone.
2.3.2. Bulk density of Itopride HCl granules
The term bulk density refers to a measure used to describe a
packing of particles of granules. A quantity of 5 g powder
for each formulation, previously lightly shaken to break any
agglomerates formed, was introduced into a 10 ml measuring
cylinder. After the initial volume was observed the cylinder
was allowed to fall under its own weight onto a hard surface
from a height of 25 cm at 2 s intervals.
The tapping was continued until no further change in vol-
ume was noted. LBD and TBD were calculated using the fol-
lowing formula:
Table 1 Composition of 14 Itopride formulations with different ratios and different grades of HPMC polymer.
Composition Formulation code
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14
Itopride HCl 50 50 50 50 50 50 50 50 50 50 50 50 50 50
HPMCK100M 0 0 0 0 30 30 0 0 15 15 15 15 10 10
HPMC K 15M 0 0 30 30 0 0 15 15 15 15 0 0 10 10
HPMC K 4M 30 30 0 0 0 0 15 15 0 0 15 15 10 10
PVP K30 0 30 0 30 0 30 0 30 0 30 0 30 0 30
Lactose 110 80 110 80 110 80 110 80 110 80 110 80 110 80
Talcum 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Magnesium stearate 5 5 5 5 5 5 5 5 5 5 5 5 5 5
IPA 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml 1ml
Total 200 200 200 200 200 200 200 200 200 200 200 200 200 200
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TBD=Weight of the powder/tapped volume of the
packing
2.3.3. Compressibility index for sustained release Granulation
The compressibility was calculated by Carr’s compressibility
index caution and wells, 1088.
Carr’s indexð%Þ ¼ ½ðTBD LBDÞ  100=TBD2.3.4. Total porosity of granules for 50 mg Itopride HCl SR
matrix tablet
Total porosity was determined by measuring the volume occu-
pied by a selected weight of a powder (Vbulk) and the true vol-
ume of granules (the space occupied by the powder exclusive of
spaces greater than the intermolecular space, V):
Porosityð%Þ ¼ Vbulk  V=Vbulk  1002.4. Tablet compression and Characterization of the compressed
tablet
Granules of both SR layers were prepared separately and
dried. These dried granules were lubricated separately with
talc and Mg-stearate. Two hundred milligrams of Itopride
HCl SR granules per each tablet was taken and compressed
on a 10 station lab press compression machine (CIP Machin-
eries Pvt. Ltd., Ahmedabad) using D tooling concave
punches.
2.5. Physical properties of sustained release tablets
The tablets were characterized immediately after the formula-
tion. The weight variation of the 20 tablets was accomplished
according to guidelines mentioned in I.P. 1996 using an elec-
tronic balance. Friability of 10 tablets was evaluated by
Roche type friabilator for 4 min at the rate of 25 rpm. For
each formulation the hardness of 10 tablets was evaluated
using Monsanto hardness tester (chambell electronics, India).
The thickness of the 10 tablets was measured by electronic
Vernier caliper (mitutoyo) japan. As the formulations one
sustained release matrix tablet so there is no scope for disin-
tegration test.2.6. Assay of Itopride HCl matrix tablet
Twenty tablets of the sustained formulation were crushed into
a ﬁne powder by mortar and pestle, 100 mg of the crushed
powders was weighed in 100 ml volumetric and diluted in a
ﬂask with methanol. After sonication for 15 min the diluted
solution was ﬁltered. The total amount of drug for each tablet
was analyzed. After the proper dilution of test solution by
using the HPLC method as described in the section against
the reference solution of pure drug powder prepared in the
same procedure. As we have chosen the HPLC so there is no
chance of detection of any degradation products.
2.7. Dissolution study of matrix tablet
Drug release of individually six tablets were measured using
USP 1 (basket type) apparatus (Electrolab, TDPOGP, USPx-
xiii) using media of 900 ml 0.1 (N) HCl for ﬁrst 2 h and the rest
of hours at pH 6.8 phosphate buffer. The dissolution media
were maintained at a temp of 37 C. The sample was with-
drawn at the internal of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h accord-
ing to preprogrammed manner. At every withdrawal the
sample was replaced with 5 ml of fresh media. All the solutions
of samples were analyzed by using high performance liquid
chromatography (HPLC) method as described later.
2.8. Optimization of sustained release formulation by response
surface methodology (RSM)
2.8.1. Experimental design
The optimization of Sustained release formulation of both
Itopride HCl was done by using the design expert software
(Design Expert trial version 7.0.3 State Inc, Minneapolis,
MN). A central composite design (CCD) with a= 1 was em-
ployed as per the standard protocol Based on prefromulation
study the amounts of HPMC K 100M (X1) and PVP K30
(X2) were selected as the independent factors, studied at three
levels each. The central point (0, 0) was studied in quintupli-
cate. All other formulation and processing variables were
kept invariant throughout the study. Table 2 summarizes
an account of the 13 experimental runs studied, their factor
combinations, and the translation of the coded levels to the
experimental units employed during the study. % of drug re-
leased in 1 h (rel1 h) (Y1), % of drug released in 8 h (rel8 h)
204 A. Bose et al.(Y2), time to 50% drug release (t50%) (Y3) were taken as the
response variables.
2.8.2. Data analysis and validation of optimization model for
matrix tablet
Various RSM computations for the current optimization study
were performed employing Design Expert software (Design
Expert trial version 7.0.3 State-Ease Inc, Minneapolis, MN).
Polynomial models including interaction and quadratic terms
were generated for all the response variables using multiple lin-
ear regression analysis (MLRA) approach. The general form
of the MLRA model is represented as the following equation:
Y ¼ b0 þ b1X1 þ b2X2 þ b3X1X2 þ b4X21 þ b5X22 þ b6X1X22
þ b7X21X2
here, b0 is the intercept representing the arithmetic average of
all quantitative outcomes of 13 runs; b1 to b7 are the coefﬁ-
cients computed from the observed experimental response val-
ues of Y; and X1 and X2 are the coded levels of the independent
variable(s). The terms X1X2 and X
2
i (i= 1–2) represent the
interaction and quadratic terms, respectively. Statistical valid-
ity of the polynomials was established on the basis of ANOVA
provision in the Design expert Software. Subsequently, the fea-
sibility and grid searches were performed to locate the compo-
sition of optimum formulations (Singh and Ahuja, 2002; 2004)
Three-dimensional (3D) response surface plots and two dimen-
sional (2-D) contour plots were constructed based on the mod-
el polynomial functions using Design Expert software. These
plots are very useful to see interaction effects on the factors
on the responses. Seven optimum checkpoints for Itopride
were selected by intensive grid search, performed over the en-
tire experimental domain, to validate the chosen experimental
design and polynomial equations. The formulations corre-
sponding to these checkpoints were prepared and evaluated
for various response properties. Subsequently, the resultant
experimental data of response properties were quantitativelyTable 2 Formulation trials of 50 mg Itopride HCl sr matrix
tablet as per experimental design.
Trial No. Coded factor levels
X1 X2
I 1 1
II 1 0
III 1 1
IV 0 1
V 0 0
VI 0 1
VII 1 1
VIII 1 0
IX 1 1
X 0 0
XI 0 0
XII 0 0
XIII 0 0
Translation of coded levels in actual units
Coded level for Domperidone 1 0 1
X1: HPMC K 100M (mg) 5 10 15
X2: PVP K30 (mg) 5 10 15
Coded level for Itopride HCl 1 0 1
X1: HPMC K 100M (mg) 20 30 40
X2: PVP K30 (mg) 20 30 40compared with those of their predicted values. Also, linear
regression plots between observed and predicted values of
the response properties were drawn using MS-Excel, forcing
the line through origin.
2.9. Computation of release kinetics of 50 mg Itopride HCl
matrix tablet
To study the mechanism of drug release from the optimized
formulation of matrix tablets, the release data were ﬁtted to
the following equations:
Zero-order equation : Qt ¼ Q0 þ k0t
Where, Qt is the amount of drug release in time t, Q0 is the ini-
tial amount of drug in the solution (most times, Q0 = 0) and
k0 is the zero order release rate.
First-order equation : lnQt ¼ lnQ0 þ k1t
Where, Qt is the amount of drug released in time t, Q0 is the
initial amount of drug in the solution and k1 is the ﬁrst order
release rate constant.
Higuchi’s equation : Q ¼ kHt1=2
Where, Q is the amount of drug release at time t, and kH is the
Higuchi diffusion rate constant.
Korsmeyer et al:’s equation ð16Þ : Mt=M1 ¼ Ktn
Where, Mt is the amount of drug released at time t, M1 is the
amount of drug released after inﬁnite time, and k is a kinetic
constant incorporating structural and geometric characteristics
of the tablet and n is the diffusion exponent indicative of the
drug release mechanism. The mechanism of drug release was
dependent on the value of ‘n’.
2.10. Surface topography of bi-layer matrix tablet by scanning
electron microscope (SEM)
Scanning electron microscopy (SEM) is a commonly used tech-
nique to examine the surface morphology of tablets and to visu-
ally support other qualitative and quantitative results
(Korsemeyer et al., 1983; Porter and Saraceni, 1988; Poukavoos
and Peck, 1993; Lehtola et al., 1995; Felton andMcginty, 1996).
In scanning electron microscope as electrons are employed, a
vacuum ismaintained inside themicroscope column to keep free
of air molecules. Generally the column is maintained at a vac-
uum of about 10 torr. Now when a narrow beam of primary
electrons are generated from the electron gun and hits the spec-
imen surface then secondary electrons are emitted from the spot.
The yield of the secondary electron depends on the angle be-
tween the direction of primary electrons and the specimen sur-
face. A ﬂat surface produces a minimum number of secondary
electrons. If the beam is moved to another spot, there also the
yields of secondary electrons would depend upon the topo-
graphical features of that region and maybe more or less than
that of the ﬁrst spot. Thus, continuous moving or scanning the
electron beam over the specimen surface achieves a correspond-
ing signal output. If the secondary electrons are also continu-
ously collected and displayed on a cathode ray tube (CRT), an
image appears which is comparable to the topographical detail
of the specimen. The SEM study was carried out for SR layer
of formulated bi-layer matrix tablet to check the surface texture
of the same. A smooth surface gives a uniform drug release
Formulation development and optimization of sustained release matrix tablet 205whereas uneven or cracked surface gives an uncontrolled and
non-uniform drug release. The study was carried out by
JEOL/JSM/5200.
3. Results and discussion
3.1. Micromeritic properties of granules
Matrix tablets were formulated according to wet granulation
method as described in Section 2. Granulation (Table 3) is
the key process in the production of matrix tablet sustained re-
lease dosage form. The properties of granules which should be
evaluated to ensure the proper formulation of the tablet dos-
age form are an important aspect in matrix tablet formulation.3.2. Physical properties of matrix tablet
All the formulated tablets containing the active drugs were
evaluated to ﬁnd the physical properties like hardness, thick-
ness, friability and drug contents (Table 4). In a weight varia-
tion test, the pharmacopeial limit of percentage deviation for
tablets whose weight is more than 250 mg is ±5%.The average
percentage deviation of all the tablets was found within the
limit which was less than 1%. Hardness of the tablets wasTable 4 Physical properties and drug content of Itopride 50 mg SR
Trial No. Friability (%) Hardness (kg/cm
Itopride Itopride
0 0.48 ± 0.12 5.2 ± 0.12
1 0.53 ± .12 4.3 ± 0.04
2 0.41 ± 0.02 5.2 ± 0.03
4 0.43 ± 0.05 5.3 ± 0.08
6 0.61 ± 0.11 4.3 ± 0.06
8 0.55 ± 0.04 4.3 ± 0.12
10 0.41 ± 0.12 5.3 ± 0.11
12 0.43 ± 0.11 5.3 ± 0.09
13 0.48 ± 0.12 5.1 ± 0.12
14 0.53 ± 0.02 5.1 ± 0.07
Table 3 Micromeretic properties of granules for different trial form
Formulation
trial
Angle of
repose
Loose bulk
density (gm/ml)
1 24.12 ± 0.08 0.42 ± 0.04
2 25.12 ± 0.05 0.442 ± 0.1
3 24.34 ± 0.18 0.412 ± 0.03
4 24.23 ± 0.11 0.453 ± 0.04
5 24.09 ± 0.05 0.432 ± 0.05
6 24.33 ± 0.07 0.422 ± 0.02
7 24.44 ± 0.11 0.411 ± 0.09
8 22.98 ± 0.05 0.443 ± 0.04
9 23.23 ± 0.06 0.422 ± 0.05
10 24.45 ± 0.03 0.411 ± 0.07
11 24.98 ± 0.11 0.422 ± 0.04
12 23.98 ± 0.06 0.410 ± 0.08
13 23.45 ± 0.18 0.397 ± 0.10
14 23.12 ± 0.18 0.432 ± 0.04found acceptable and uniform from batch to batch variation.
The drug content was also found uniform and within the pre-
scribed limit.
3.3. Dissolution study of 50 mg Itopride HCl SR matrix tablet
3.3.1. Chromatographic analysis
Dissolution samples were analyzed by HPLC-UV method de-
scribed in Section 2. Fig. 1 shows the representative chromato-
gram of a dissolution sample showing separation of Itopride
HCl and Domperidone (internal standard) at 2.077 and
4.167, respectively.
3.3.2. In vitro release of Itopride from SR matrix tablet
Mean cumulative % release of Itopride at different time inter-
vals are shown in Fig. 2. The dissolution proﬁle for both the
formulations was found to be different from batch to batch.
But the formulation of f6 was found to be the most desired re-
lease proﬁle for the formulation. The release of formula f6 was
most consistent, accurate and complete. After the evaluation
of dissolution study it can be concluded that the F6 formula-
tion for the matrix tablet containing HPMC K 100 with PVP
K30 possesses excellent drug release kinetics. The formulation
of F6 also possesses good micromeritic and physical proper-
ties. The f6 formulation was selected for further experiment.matrix tablet.
2) Thickness (mm) Drug content (%)
Itopride Itopride
4.5 ± 0.15 98.03 ± 0.12
4.4 ± 0.12 97.09 ± 0.12
4.6 ± 0.08 97.07 ± 0.03
4.4 ± 0.16 98.03 ± 0.12
4.4 ± 0.09 97.09 ± 0.12
4.6 ± 0.28 94.03 ± 0.12
4.4 ± 0.15 95.09 ± 0.12
4.3 ± 0.15 97.03 ± 0.12
4.4 ± 0.17 98.09 ± 0.12
4.6 ± 0.13 99.12 ± 0.12
ulation of Itopride 50 mg SR matrix tablet.
Tapped bulk
density (gm/ml)
Compressibility
index (%)
Total
porosity (%)
0.553 ± 0.10 15.08 ± 0.11 24.01 ± 0.14
0.532 ± 0.11 14.07 ± 0.04 23.09 ± 0.13
0.512 ± 0.09 12.06 ± 0.08 24.05 ± 0.23
0.522 ± 0.08 11.06 ± 0.11 22.02 ± 0.19
0.502 ± 0.14 14.00 ± 0.14 23.13 ± 0.21
0.512 ± 0.20 12.06 ± 0.07 27.21 ± 0.11
0.598 ± 0.09 13.11 ± 0.11 24.12 ± 0.12
0.532 ± 0.10 14.09 ± 0.09 26.09 ± 0.32
0.509 ± 0.08 13.23 ± 0.11 20.54 ± 0.25
0.522 ± 0.06 15.12 ± 0.15 26.32 ± 0.32
0.512 ± 0.14 14.08 ± 0.09 22.29 ± 0.21
0.533 ± 0.09 12.03 ± 0.08 21.19 ± 0.49
0.521 ± 0.07 11.04 ± 0.06 26.75 ± 0.20
0.512 ± 0.15 14.05 ± 0.11 25.09 ± 0.12
206 A. Bose et al.Now the objective of our study is to evaluate the effect of inde-
pendent factors i.e. PVP K30 and HPMC on different response
variables. And then to ﬁnd the ratio of two independent vari-
ables in that formulation which will possess our desired release
kinetics.
3.4. RSM optimization results of Itopride HCl
For optimization of the Itopride formulation we had selected
central composite design. In central composite design the three
response variables and two independent variables were taken
for Itopride 50 mg SR .The response variables are Release in
1 h, t50% and Release in 8 h .The independent variables areFigure 1 Representative chromatogram showing separation of
Itopride at 2.077 and Domperidone at 3.09 min.
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Figure 2 Mean cumulative % drug release proﬁles of Itopride
HCl matrix formulations prepared as per the experimental design.HPMC K100 (A) and PVP K30 (B) all the in vitro release ki-
netic properties of Itopride for 13 formulations are shown in
Table 5. Three different concentrations of HPMC K100 and
PVP K30 were used to evaluate different independent release
kinetics.
3.4.1. Mathematical modeling of RSM optimization of Itopride
HCl
Mathematical relationships in the form of polynomial equa-
tion for the measured response (Release in 1 h, t50% and release
in 8 h) were obtained with the stat-ease software. The polyno-
mial equation relating the different response and independent
variable is given below:
R1ðrel1 hÞ ¼ þ10:93 1:43Aþ 0:17Bþ 1:46AB
þ 5:517E003A2  0:054B2
R2ðt50%Þ ¼ þ5:30þ 0:66Aþ 0:057B 0:19AB 0:16A2
þ 0:26B2
R3ðrel8 hÞ ¼ þ0:80 0:041A 0:083Bþ 0:060ABþ 0:042A2
þ 0:048B2
The above equation represents the quantitative effect of pro-
cess variables and their interaction on the response. For esti-
mation of the signiﬁcance of the model, the analysis of
variance (ANOVA) was determined as per the provision of de-
sign expert software as shown in Tables 6–8. Using 5% signif-
icance level, a model is considered signiﬁcant if the p-value
(signiﬁcance probability value) is less then 0.05.
3.4.2. Response surface analysis (release in 1 h)
Figs. 3 and 4 represent the contour plot and three dimensional
analysis for the studied response properties of release in 1 h.
From the contour plot it can be concluded that the release in
1 h decreases with augmentation of both the variables. The re-
sponse changes the variables in a nonlinear and descending
manner. But the contour plot shows that HPMC has a com-
pletely greater inﬂuence on the response variables than PVP
K30. From the contour plot it was evident that the declining
trend was obtained with ascending order of HPMC. However
very little effect was observed until the intermediate levels of
PVP K30 were reached, after which a declining trend was ob-
served at increasing the concentration of PVP K30.
3.4.3. Response surface analysis (t50%)
Figs. 5 and 6 demonstrate the relation of t50% (Time to 50%
drug release) with PVP K30 and HPMC. The effect of PVP
and HPMC was found to be in an ascending manner i.e.
increasing the amount of both increases the response. The
effect of PVP was found to be little throughout different con-
centrations. The effects of HPMC were found to be linear at
low concentrations but at high concentrations it shows non lin-
ear response. From the contour and 3D plot it is quite evident
that HPMC has a comparatively grater inﬂuence on the re-
sponse variables than PVP-K30.
3.4.4. Response surface analysis (release in 8 h)
Figs. 7 and 8 represent the contour plot and three dimensional
analysis for the studied response properties of release in 8 h.
From the contour plot it can be concluded that release in 8 h
Table 5 Response variables (R1–R3) obtained from various trial formulations of Itopride HCl 50 mg SR tabletsa.
Run Factor 1 HPMC
K100, mg (A)
PVP K30 (B) Release at
1 h % (R1)
t50% (R2) Release at
8 h % (R3)
1 30.00 30.00 10.96 5.18 69.07
2 20.00 30.00 11.93 4.78 72.38
3 20.00 20.00 14.54 4.13 78.3
4 20.00 40.00 10.54 5.06 69.58
5 40.00 20.00 8.84 6.07 63.73
6 30.00 30.00 11.36 5.12 69.43
7 30.00 40.00 11.96 5.25 67.46
8 40.00 30.00 8.9 5.63 67.53
9 40.00 40.00 10.67 6.23 61.42
10 30.00 30.00 11.02 5.39 66.89
11 30.00 30.00 11.17 5.34 68.09
12 30.00 20.00 8.75 6 62.7
13 30.00 30.00 11.21 5.36 68.39
a A: HPMC K 100M; B: PVP K30; rel1 h: release in 1 h; rel8 h: release in 8 h; t50%: time to 50% drug release.
Table 6 ANOVA for response surface quadratic model for release in 1 h. Analysis of variance table [Partial sum of squares - Type
III].
Source Sum of squares df Mean square F value p-value Prob > F
Model 21.01 5 4.20 3.74 <0.0001 Signiﬁcant
A 12.33 1 12.33 10.97 0.0129
B-B 0.18 1 0.18 0.16 .7007
AB 8.50 1 8.50 7.56 0.0285
A2 8.407E-005 1 8.407E-005 7.481E-005 0.9933
B2 8.198E-003 1 8.198E-003 7.295E-003 0.9343
Residual 7.87 7 1.12
Lack of ﬁt 7.77 3 2.59 0.60 0.0003
Pure error 0.10 4 0.025
Cor total 28.8812 12
Table 7 ANOVA for response surface quadratic model for t50%. Analysis of variance table [Partial sum of squares - Type III].
Source Sum of squares df Mean square F value p-value Prob > F
Model 2.98 5 0.60 5.19 0.0262 Signiﬁcant
A-A 2.61 1 2.61 22.74
B-B 0.019 1 0.019 0.17 0.6945
AB 0.15 1 0.15 1.29 0.2935
A2 0.070 1 0.070 0.61 0.4595
B2 0.19 1 0.19 1.63 0.2426
Residual 0.80 7 0.11
Lack of ﬁt 0.75 3 0.25 17.27 0.0094
Pure error 0.058 4 0.014
Cor total 3.78 12
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sponse changes the variables in a linear and descending man-
ner. But the contour plot shows that HPMC has a
completely greater inﬂuence on the response variables than
PVP-K30. From the contour plot it is evident that the declin-
ing trend obtained with ascending order of HPMC.
3.4.5. Optimization of the independent variables of Itopride HCl
This was the most important part of response surface method-
ology. The formulation of the drug which released the drug incontrolled and complete manner was selected for optimum
formulation. The criteria for optimum formulation of Itopride
HCl are given in Table 9.
3.4.6. Validation of RSM results of Itopride 50 mg SR
Response surface methodology gave us seven solutions where
the results of the physical evaluation and tablets assay were
found within limits.Table 10 lists the composition, their pre-
dicted and experimental values of all response variables and
the percentage error. The formulation number T\ 6 was
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Figure 3 Contour plot showing the effect of the amount of polymer HPMC K 100M and binder (PVP K30) on drug release at 1 h from
Itopride SR matrix tablet.
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Figure 4 Response surface plot (A) showing the effect of the amount of polymer HPMC K 100M and binder (PVP K30) on drug release
at 1 h from Itopride SR matrix tablet.
208 A. Bose et al.chosen as the best optimized formula for Itopride SR as the er-
ror was minimum for the response of the dependent variables.
The composition of the formula is given below (Table 11).
3.5. Computation of release mechanism of Itopride HCl
The release data were evaluated by applying the equation of
zero order, ﬁrst order, Higuchi and Korsmeyer equation.
The regression coefﬁcient values of different release kinetic
equations evaluated from the dissolution proﬁle of developed
formulation are compared in Table 12. It can be highly postu-lated that in vitro release proﬁle of all the matrix formulations
could be best expressed by the Higuchi model. The plot
showed high linearity in comparison to other release kinetic
equations. Release of drug from the matrix tablet generally fol-
lows diffusion for water soluble drug and erosion or relaxation
for water insoluble drug. Diffusion is related to transport drug
from the dosage matrix into the in vitro study ﬂuid depending
on the concentration gradient between dosage form and
in vitro ﬂuid. As gradient varies, the drug is released and the
distance for diffusion increases. This could explain why the
drug diffuses at a comparatively slower rate. As the dissolution
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Figure 5 Contour plot showing the effect of the amount of polymer HPMC K 100M and binder (PVP K30) on t50% from Itopride SR
matrix tablet.
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Figure 6 Response surface plot (A) showing the effect of the amount of polymer HPMC K 100M and binder (PVP K30) on drug release
at t50% from Domperidone SR.
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uchi kinetics. To conﬁrm diffusional mechanism, the data were
ﬁtted into Korsmeyer et al.’s equation. For matrix tablet, n va-
lue 0.5 indicates diffusion controlled value to near 1.00 indi-cates erosion. Intermediate value suggests simultaneous
diffusion and erosion contribute to overall release mechanism.
As the Itopride is water soluble drug diffusion is the main drug
release mechanism.
Figure 7 Contour plot showing the effect of the amount of polymer HPMC K 100M and binder (PVP-K30) on release in 8 h from
Itopride SR matrix tablet.
Figure 8 Response surface plot (A) showing the effect of the amount of polymer HPMC K 100M and binder (PVP K30) on drug release
in 8 h from Itopride HCl SR matrix tablet.
210 A. Bose et al.3.6. Surface topography of bi-layer matrix tablet by scanning
electron microscope (SEM)
Scanning electron microscopy (SEM) was performed to
determine the surface topography of SR layer of matrix tab-let. The SEM photographs of intact SR layer of Itopride
after 1 h of dissolution study and after 4 h of dissolution
study and after 8 h of dissolution study are given in Fig. 9.
It showed intact surface only swells without any perforations,
channels, or troughs. After dissolution, the solvent front en-
Table 8 Response R3 ANOVA for response surface quadratic model analysis of variance table [Partial sum of squares - Type III].
Source Sum of squares df Mean square F value p-value Prob > F
Model 167.43 5 33.49 4.26 0.0424 Signiﬁcant
A-A 126.78 1 126.78 16.14 0.0051
B-B 6.55 1 6.55 0.83 0.3914
AB 10.27 1 10.27 1.31 0.2904
A2 15.28 1 15.28 1.94 0.2058
B2 17.58 1 17.58 2.24 0.1782
Residual 54.98 7 7.85
Lack of ﬁt 51.10 3 17.03 1.55 0.0091
Pure error 3.88 4 0.97
Cor total 222.41 12
Table 9 Release kinetics of optimum formulation.
Release property Range
Release in 1st hour 12.2–14.54
Time for 50% release 5–6
Release in 8th hour 70–78.3
Table 11 Final optimized formulation of Itopride 50 mg SR
layer.
Particulars Amount (mg)
Itopride HCl 50
HPMC K100M 24.65
PVP K30 20
Talc 5
Magnesium stearate 5
Lactose q.s.
IPA 1 ml
Total 200 mg
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tablet. The drug diffuses out of the matrix after it comes
in contact with dissolution medium. The images of the tablet
showed a network in the swollen polymer through which the
drug diffused to the surrounding medium. Thus, it was con-
cluded that the drug was released from matrix by diffusion
mechanism. During in-vitro dissolution study, the HPMC
K100M swells as the dissolution media enter into the poly-
mer matrix. The surface becomes smooth and uniform which
results in a slower and controlled drug release. SEM study of
Itopride matrix tablets further conﬁrmed both diffusion and
erosion mechanisms (Fig. 9) to be operative during drug re-
lease from the optimized batch of matrix tablet. SEM photo-
micrograph of the matrix tablet taken at different time
intervals after the dissolution experiment showed that the
matrix was intact and pores had formed throughout the ma-
trix. SEM photomicrographs of tablet surface at different
time intervals also showed that erosion of matrix increased
with respect to time indicated by the photomicrographs at
2, 4 and 8 h revealing pores with increasing diameter. These
photomicrograph also revealed the formation of gelling
structure indicating the possibility of swelling of matrix tab-Table 10 Composition of the check point formulations, the predict
No. HPMC K 100 PVP K30 Release in 1 h T
Predicted Experimental Error P
1 24.80 20.18 12.2019 13.25 0.08 5
2 24.74 20.08 12.2244 10.25 0.16 5
3 24.68 20.22 12.2339 11.32 0.07 5
4 24.72 20.32 12.2185 10.32 0.15 5
5 24.82 20.08 12.2024 13.25 0.08 5
6 24.65 20.06 12.251 14.35 0.17 5
7 24.74 20.40 12.208 13.02 0.06 5lets (Fig. 9). Hence, the formation of both pores and gelling
structure on tablet surface indicates the involvement of both
erosion and diffusion mechanisms to be responsible for sus-
taining the release of Itopride from formulated matrix
tablets.
4. Conclusion
The sustained release matrix tablets of Itopride HCl formula-
tion system includes the drug delivery system that achieves
slow and extended release of the drug over an extended period
of time. The response variables of the formulation are opti-
mized by Response surface methodology(ccd design).The
in vitro dissolution release kinetics and morphology of the
matrix tablet analyzed by the SEM indicate the successful sus-
tenance of the matrix tablet for several hours.ed and experimental values of response variables.
50% Release in 8 h
redicted Experimental Error Predicted Experimental Error
.01351 5.65 0.12 70.59 69.02 0.022
.01111 4.65 0.07 70.61 71.25 0.231
.00002 5.25 0.04 70.70 72.32 0.022
.00039 4.75 0.05 70.70 69.95 0.010
.01896 5.03 0.99 70.54 68.25 0.032
.00244 5.02 0.003 70.68 71.25 0.008
.00033 5.11 0.021 70.70 69.25 0.020
Figure 9 Surface of SR layer of Itopride HCl (a) (after 1 h of dissolution), (b) (after 4 h of dissolution), (c) (after 8 h of dissolution)
investigating by scanning electron microscope (SEM).
Table 12 In vitro release kinetics of 50 mg Itopride HCl SR matrix tablet.
Trial No. Zero order R2 First order R2 Higuchi R2 Koresmeyer R2 Koresmeyer Release exponent (n)
F1 0.9820 0.8500 0.9872 0.9826 0.4452
F2 0.9954 0.8786 0.9875 0.9960 0.4420
F3 0.9851 0.8532 0.9860 0.9858 0.4340
F4 0.9629 0.7885 0.9931 0.9719 0.4400
F5 0.9602 0.7858 0.9926 0.9709 0.4200
F6 0.9462 0.7887 0.9857 0.9696 0.4500
F7 0.9073 0.7807 0.9700 0.9700 0.4900
F8 0.9970 0.8817 0.9855 0.9975 0.4100
F9 0.9608 0.7892 0.9921 0.9716 0.4700
F10 0.9874 0.8325 0.9957 0.9886 0.4400
F11 0.9650 0.8305 0.9956 0.9878 0.4460
F12 0.9914 0.8505 0.9939 0.9929 0.4550
F13 0.9426 0.7997 0.9860 0.9741 0.4440
R2 = Linear regression coefﬁcient.
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